We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 174

Experimental testing in patent actions: federal court issues notice to the profession

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • July 16 2014

Experimental testing and patent infringement actions often go hand in hand. With respect to providing notice of experimental testing to other parties

Federal Court of Appeal updates Section 8 damages law

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • July 9 2014

On March 14 2014 the Federal Court of Appeal issued its highly anticipated decisions concerning claims by Teva and Apotex for damages pursuant to

Patentability of computer-implemented inventions: how Canada compares to the United States in view of Alice corp

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, USA
  • -
  • July 7 2014

Every patentee must understand that each patent system has evolved a unique way in which to effectively deal with the limits of patentable subject

Personalized medicine: patent issues in Canada and Europe

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, European Union
  • -
  • June 19 2014

"Personalized medicine," in its broadest aspects, is essentially the tailoring of treatments to individual characteristics, needs and preferences

Permanent injunction granted despite patentee not having a product that practiced the claims of the patent

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 18 2014

On May 22, 2014, the Federal Court of Canada issued an injunction curtailing Janssen Inc.’s marketing of its drug ustekinumab (STELARA) in ongoing

Canadian first filing: something worth considering

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 14 2014

International patent strategies for many applicants have typically involved filing first in the United States to establish a priority claim. The

New guideposts for the fact-intensive hypothetical world of generic damages claims

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 14 2014

The past year has seen significant evolution in the Canadian law of generic pharmaceutical damages claims under section 8 of the Patented Medicines

Court of Appeal rejects generic's punitive damages claim in Viagra Case

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 9 2014

On May 27, 2014, the Federal Court of Appeal upheld the striking of portions of Teva Canada Limited's Statement of Claim seeking punitive and

Patented Medicines Prices Review Board jurisdiction is limited by the Federal Court

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 29 2014

On May 27, 2014, Justice O'Reilly of the Federal Court released two decisions relating to the jurisdiction of the Patented Medicines Prices Review

Federal Court affirms standing for innovative drug manufacturer

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 24 2014

What rights do innovative drug manufacturers have in situations where generics challenge certain Health Canada decisions but do not name the